Company Profile For Cornerstone Therapeutics Inc.

Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. On October 31, 2008, the Company completed the merger with Cornerstone BioPharma. The product development pipeline includes two SPECTRACEF line extensions: a once daily dosage tablet, or SPECTRACEF Once Daily, and an oral suspension for the pediatric market, or SPECTRACEF Suspension. The product development pipeline also includes three additional product candidates: an anticholinergic, or drying agent, and antihistamine combination product candidate for the treatment of symptoms of allergic rhinitis and two antitussive, or cough suppressant, and antihistamine combination product candidates. The SPECTRACEF product line includes SPECTRACEF 200 milligram and SPECTRACEF 400 milligram for the treatment of mild to moderate infections caused by pathogens associated with particular respiratory tract infections.

BRIEF: For the six months ended 30 June 2009, Cornerstone Therapeutics, Inc.'s revenues totaled $55.7M, up from $23.5M. Net income totaled $8.1M, up from $2.8M. Revenues reflect higher income from the sale of ALLERX 10 Dose Pack/ALLERX 30 Dose Pack, increased income from SPECTRACEF product and the presence of income from ZYFLO CR & ZYFLO product. Net income also reflects improved gross profit margins and a decrease in interest expense-net.

Cornerstone Therapeutics Inc.
2000 Regency Parkway
Suite 255
Cary   NC   27518
P: +1919.6786611

129